Lipids & metabolic liver disease

Remnant–to–LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia atrial fibrillation (AF) project III (MAFP-III) cohort study

Cardiovasc DiabetolPublished Prospective cohort study

Main finding · Thromboembolic events, low LDL-C groupResult — go to the resultAdjusted hazard ratio 1.82 95% CI 1.03–3.23

Authors' conclusion

Despite low LDL-C levels in AF patients, elevated RC levels were still independently associated with a higher thromboembolic risk, suggesting discordance between RC and LDL-C in risk stratification among patients with AF.

Study context

Population
AF outpatients initiating oral anticoagulation, January 2016–November 2021; 52.5% female, median age 76 years (IQR 69–82); stratified into 4 groups by baseline low-density lipoprotein cholesterol (LDL-C) and remnant cholesterol (RC)
Participants
1,694 outpatients
Exposure
High vs low RC levels across LDL-C strata
Outcome
Composite of thromboembolic events
Follow-up
Mean 1.86 years, SD 0.4 years
Methodological detailsMAFP-III cohort
  • MAFP-III cohort

Main finding

Thromboembolic events, low LDL-C group

Adjusted hazard ratio

1.82

95% CI 1.03–3.23

P = 0.039

High RCvs Low RC
aHR 1.82 (95% CI 1.03–3.23); P = 0.039

As reported in the abstract

Thromboembolic events, overall cohort
5.7% (97)
Low LDL-C group: significant linear association between RC levels and thromboembolic risk on restricted cubic spline (RCS) analysis
p-overall = 0.044

Observational data: associations, not effects.

Secondary outcomes

Major adverse cardiovascular events (MACE), CV death and all-cause death

Higher RC levels not significantly associated with increased adverse event risk in either LDL-C group

Original publication

Remnant–to–LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study. Cardiovasc Diabetol. Published 10 July 2025. doi:10.1186/s12933-025-02831-4

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.